Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 12,523 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Ovarian Cancer
Interventions: INCB123667; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 38
States / cities: Mobile, Alabama • Los Angeles, California • San Diego, California + 35 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: NYX-2925, Placebo; Drug
Lead sponsor: Aptinyx; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Phoenix, Arizona • Anaheim, California • Fresno, California + 29 more

Conditions: Cystic Fibrosis
Interventions: AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more

Conditions: Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma
Interventions: LV305, G305, LV305-matching placebo, G305-matching placebo; Biological · Other
Lead sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 12 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Breast Cancer
Interventions: Proton Therapy; Radiation
Lead sponsor: Proton Collaborative Group; Network
Eligibility: 19 Years and older · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2041
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Diego, California • Jacksonville, Florida + 5 more

Conditions: Colitis, Ulcerative
Interventions: Vedolizumab, Adalimumab placebo, Adalimumab, Vedolizumab placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 771 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 77
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273.214, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 2 Months to 6 Months
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 39
States / cities: Bessemer, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel; Combination Product · Biological · Drug
Lead sponsor: Rakuten Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 5 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Pemziviptadil (PB1046) Injection; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 16
States / cities: La Jolla, California • Sacramento, California • Miami, Florida + 10 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 34
States / cities: Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more

Conditions: Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus), CLE
Interventions: VENT-03, Placebo; Drug
Lead sponsor: Ventus Therapeutics U.S., Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Beverly Hills, California • Clearwater, Florida • DeBary, Florida + 12 more

Conditions: Non-alcoholic Steatohepatitis
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 130
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more

Conditions: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions: Pranactin citric solution; Other
Lead sponsor: Otsuka America Pharmaceutical; Industry
Eligibility: 3 Years to 18 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Miami, Florida • El Paso, Texas • Houston, Texas

Conditions: Maternal Behavior, Infant Behavior
Interventions: Infant-Directed Singing Coaching; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 3 Months and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Atrial Fibrillation, Stroke
Interventions: WATCHMAN Left Atrial Appendage Closure Technology, Warfarin; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 58
States / cities: Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 46 more

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, Placebo; Drug · Other
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 137
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 105 more

Conditions: Hemophilia A
Interventions: SB-525 (PF-07055480); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 22
States / cities: Little Rock, Arkansas • Duarte, California • Sacramento, California + 7 more

Conditions: Lower Limb Loss
Interventions: Not listed
Lead sponsor: Miami VA Healthcare System; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pain, Postoperative
Interventions: fentanyl; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more

Conditions: SCID
Interventions: Busulfan, Cell processing for TCRαβ+/CD19+ depletion; Drug · Device
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 0 Years to 2 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more

Conditions: Spinal Injuries, Adhesions
Interventions: DuraGen Plus Adhesion Barrier Matrix; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 36
States / cities: Mobile, Alabama • Beverly Hills, California • Los Angeles, California + 31 more

Conditions: Non Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Lucence Health Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Honolulu, Hawaii + 2 more

Conditions: Pain
Interventions: Oxycodone HCl controlled-release tablets; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 35
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more

Conditions: Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
Interventions: Not listed
Lead sponsor: PYC Therapeutics; Industry
Eligibility: 8 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Miami, Florida • Seattle, Washington

Search by objective public record fields.

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

POCone-UBiT-IR300 Pediatric Comparison Study

Infant-Directed Singing for At-Risk Mothers and Infants

WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation

A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Musculoskeletal Measurements in Transfemoral Amputees

Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants

Conditioning SCID Infants Diagnosed Early

DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery

LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation